Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Cash & Current Investments (2024 - 2025)

Evommune (EVMN) has disclosed Cash & Current Investments for 2 consecutive years, with $149.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 107.11% to $149.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $149.2 million, a 107.11% increase, with the full-year FY2025 number at $149.2 million, up 107.11% from a year prior.
  • Cash & Current Investments was $149.2 million for Q4 2025 at Evommune, up from $76.1 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $149.2 million in Q4 2025 to a low of $18.1 million in Q3 2024.